Ambalal Sarabhai Enterprises Ltd Stock Price Today (NSE: AMBALALSA)
Fundamental Score
Ambalal Sarabhai Enterprises Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Ambalal Sarabhai Enterprises Ltd share price today is ₹32.57, up +0.71% on NSE/BSE as of 17 June 2026. Ambalal Sarabhai Enterprises Ltd (AMBALALSA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹218.56 (Cr). The 52-week high for AMBALALSA share price is ₹38.85 and the 52-week low is ₹23.12. At a P/E ratio of 13.99x, AMBALALSA is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 6.25% and a debt-to-equity ratio of 0.32.
Ambalal Sarabhai Enterprises Ltd Share Price Chart — NSE/BSE Historical Performance
Ambalal Sarabhai Enterprises Ltd share price chart: 14.78% return over the past month. 52-week high ₹38.85, 52-week low ₹23.12.
Ambalal Sarabhai Enterprises Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹34.93 | ₹38.85 | ₹34.92 | ₹37.20 | 86.14K (Cr) | |
| ₹34.40 | ₹36.80 | ₹34.40 | ₹35.29 | 87.22K (Cr) | |
| ₹35.48 | ₹36.58 | ₹33.50 | ₹35.69 | 94.81K (Cr) | |
| ₹32.01 | ₹35.77 | ₹32.01 | ₹34.88 | 1.10L (Cr) | |
| ₹32.81 | ₹33.34 | ₹31.50 | ₹32.40 | 43.31K (Cr) | |
| ₹34.45 | ₹34.45 | ₹32.00 | ₹32.16 | 22.17K (Cr) | |
| ₹33.89 | ₹34.67 | ₹32.65 | ₹33.07 | 76.68K (Cr) | |
| ₹34.38 | ₹34.80 | ₹31.80 | ₹32.66 | 60.26K (Cr) | |
| ₹31.98 | ₹33.38 | ₹31.40 | ₹32.75 | 41.29K (Cr) | |
| ₹31.60 | ₹32.34 | ₹31.03 | ₹31.32 | 15.27K (Cr) |
Ambalal Sarabhai Enterprises Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹34.40 | ₹38.85 | ₹34.40 | ₹37.20 | +8.14% | |
| ₹31.04 | ₹36.58 | ₹30.00 | ₹35.69 | +14.98% | |
| ₹25.13 | ₹36.00 | ₹24.05 | ₹31.80 | +26.54% | |
| ₹25.01 | ₹29.25 | ₹23.90 | ₹24.27 | -2.96% | |
| ₹28.89 | ₹29.85 | ₹25.06 | ₹26.24 | -9.17% | |
| ₹28.59 | ₹29.44 | ₹23.12 | ₹27.58 | -3.53% | |
| ₹28.42 | ₹33.00 | ₹25.97 | ₹28.58 | +0.56% | |
| ₹33.40 | ₹33.40 | ₹28.26 | ₹28.40 | -14.97% | |
| ₹32.64 | ₹38.50 | ₹31.50 | ₹32.55 | -0.28% | |
| ₹31.99 | ₹35.00 | ₹30.06 | ₹32.64 | +2.03% | |
| ₹33.10 | ₹35.85 | ₹30.00 | ₹31.40 | -5.14% | |
| ₹36.51 | ₹37.00 | ₹31.62 | ₹33.16 | -9.18% |
AI Research Briefing
Powered by Gemini · 2026-04-17
A micro-cap generics play banking on government handouts while its fundamentals erode.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Recent news focuses on the India Pharma 2026 event, highlighting the need for enhanced funding and infrastructure to boost pharmaceutical innovation. Ambalal Sarabhai Enterprises submitted a SEBI compliance certificate for the March 2026 quarter.
CORE STORY (THE REAL GAME)
Ambalal Sarabhai Enterprises is a micro-cap pharmaceutical company attempting to ride the broader 'Make in India' wave within the pharma sector. It's a generics play with API manufacturing capabilities, hoping to benefit from government initiatives and reduced regulatory hurdles.
- Favorable government policies for the pharma sector
- Reduced regulatory hurdles for clinical trials
- Potentially undervalued compared to industry peers
- Significant order wins
- Positive earnings surprises
- Further government incentives for domestic pharma
- Micro/SME cap = liquidity risk
- Negative free cash flow
- Declining profit growth
FII decreased their holding by 0.04%. Promoter holding steady at 31.35%.
India Pharma 2026 highlighting policy push and innovation driving sectoral growth.
No, Free Cash Flow 5Y: ₹-5.46 Cr
Hoping to transition from generics to frontier biologics and novel molecules. This is a long shot.
Primary Thesis Risk
Reliance on government support with weak fundamentals.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Ambalal Sarabhai Enterprises Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Ambalal Sarabhai Enterprises Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AMBALALSA across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Attractive Valuation (P/E: 13.99 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (6.25%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.12%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-121.37%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (-8.94% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-8.94% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-5.46 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.34%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Ambalal Sarabhai Enterprises Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Ambalal Sarabhai Enterprises Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Ambalal Sarabhai Enterprises LtdAmbalal Sarabha...Selected✓ AMBALALSA • 500009 | 17.2/100 | ₹32.57₹33 | ₹218.56₹218.56 | 13.99Average 14.0 Average | 6.25%Poor 6.25% Poor | 9.12%Poor 9.12% Poor | 0.32Excellent 0.3 Excellent | -8.94%Poor -8.94% Poor | 8.08%Good 8.08% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1782.20₹1782 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6623.00₹6623 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4420.90₹4421 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1401.30₹1401 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1278.20₹1278 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2267.70₹2268 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1089.00₹1089 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2336.10₹2336 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1462.30₹1462 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5251.50₹5252 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Ambalal Sarabhai Enterprises Ltd PE Ratio History
Historical price-to-earnings ratio for AMBALALSA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹0.74 | ₹53.58 | 72.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Ambalal Sarabhai Enterprises Ltd Quarterly Performance
Latest quarterly metrics for AMBALALSA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-0.56%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-121.37%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
8.08%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-8.94%
Compounded annual net profit growth over 5 years
Ambalal Sarabhai Enterprises Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AMBALALSA — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Ambalal Sarabhai Enterprises Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Ambalal Sarabhai Enterprises Ltd (AMBALALSA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Ambalal Sarabhai Enterprises Ltd
About AMBALALSA (Ambalal Sarabhai Enterprises Ltd)
Ambalal Sarabhai Enterprises Ltd is a pioneer in the Indian pharmaceutical landscape, forging a legacy of innovation and commitment to healthcare solutions. Rooted in a rich histor...y, the company has evolved into a multifaceted organization dedicated to developing, producing, and distributing a diverse portfolio of pharmaceutical products. From addressing critical therapeutic areas like oncology and infertility to providing essential generic medications and animal health solutions, AMBALALSA strives to meet the evolving needs of patients and healthcare professionals. The company's emphasis on research and development ensures a steady pipeline of novel formulations and therapeutic advancements, solidifying its position as a trusted partner in promoting health and well-being. Driven by a pursuit of scientific excellence, AMBALALSA boasts state-of-the-art manufacturing facilities adhering to stringent global quality standards. This dedication to quality permeates every aspect of its operations, from sourcing raw materials to rigorous testing and packaging processes. The company's product range spans a wide spectrum, including specialized treatments for uro-gynaecological conditions, vital antifungal active ingredients, and vitamin C formulations. In addition to pharmaceuticals, AMBALALSA also offers analytical instruments and measuring tools, catering to the needs of research institutions and quality control laboratories. This holistic approach positions AMBALALSA as a comprehensive solution provider in the healthcare ecosystem. Beyond its core pharmaceutical offerings, AMBALALSA demonstrates a commitment to global reach, actively exporting its products to international markets. This strategic expansion reflects the company's ambition to improve access to quality healthcare worldwide. AMBALALSA also supports the pharmaceutical industry by supplying finished dosage forms and active pharmaceutical ingredients to other manufacturers. As it navigates the complexities of the modern healthcare landscape, AMBALALSA remains steadfast in its mission to enhance patient outcomes through innovative products, uncompromising quality, and a dedication to ethical practices, thereby solidifying its position as a significant contributor to the advancement of pharmaceutical science and patient care.
Company Details
Key Leadership
AMBALALSA Share Price: Frequently Asked Questions
What is the current share price of Ambalal Sarabhai Enterprises Ltd?
Ambalal Sarabhai Enterprises Ltd (AMBALALSA) trades at ₹32.57 on NSE and BSE. Market cap ₹218.56 (Cr). Educational data only.
What is the P/E ratio of Ambalal Sarabhai Enterprises Ltd?
Ambalal Sarabhai Enterprises Ltd has a P/E of 13.99x vs industry average 31.77x.
What is the Bull Run score for Ambalal Sarabhai Enterprises Ltd?
Ambalal Sarabhai Enterprises Ltd has a Bull Run score of 17.2/100 based on 25+ financial parameters.
Does Ambalal Sarabhai Enterprises Ltd pay dividends?
Ambalal Sarabhai Enterprises Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Ambalal Sarabhai Enterprises Ltd?
Ambalal Sarabhai Enterprises Ltd has ROE of 6.25%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Ambalal Sarabhai Enterprises Ltd?
Ambalal Sarabhai Enterprises Ltd has debt-to-equity of 0.32.
Is Ambalal Sarabhai Enterprises Ltd a good investment?
Bull Run gives Ambalal Sarabhai Enterprises Ltd a score of 17.2/100. This is not investment advice — consult a SEBI-registered advisor.